Werewolf Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.54 Insider Own0.70% Shs Outstand27.39M Perf Week-28.90%
Market Cap126.56M Forward P/E- EPS next Y-2.76 Insider Trans-1.32% Shs Float21.98M Perf Month-4.58%
Income-114.80M PEG- EPS next Q-0.47 Inst Own79.40% Short Float4.15% Perf Quarter-45.98%
Sales- P/S- EPS this Y-967.90% Inst Trans0.12% Short Ratio2.63 Perf Half Y-75.17%
Book/sh5.09 P/B0.78 EPS next Y68.00% ROA-64.40% Target Price20.00 Perf Year-66.67%
Cash/sh4.50 P/C0.88 EPS next 5Y- ROE-71.40% 52W Range3.51 - 21.67 Perf YTD-66.75%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-80.90% Beta-
Dividend %- Quick Ratio13.20 Sales past 5Y- Gross Margin- 52W Low17.94% ATR0.70
Employees39 Current Ratio13.20 Sales Q/Q- Oper. Margin- RSI (14)42.54 Volatility16.27% 14.53%
OptionableYes Debt/Eq0.00 EPS Q/Q84.90% Profit Margin- Rel Volume0.27 Prev Close3.96
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume347.40K Price4.14
Recom1.40 SMA20-14.04% SMA50-11.51% SMA200-63.20% Volume17,994 Change4.55%
Sep-10-21Initiated BofA Securities Buy $26
May-25-21Initiated SVB Leerink Outperform $29
May-25-21Initiated Jefferies Buy $22
May-25-21Initiated H.C. Wainwright Buy $32
May-25-21Initiated Evercore ISI Outperform $23
May-10-22 07:00AM  
Apr-08-22 02:29PM  
Apr-07-22 09:25AM  
Mar-24-22 07:00AM  
Mar-16-22 08:00AM  
Mar-15-22 08:00AM  
Feb-08-22 08:00AM  
Jan-26-22 06:53AM  
Jan-05-22 08:00AM  
Dec-14-21 04:01PM  
Dec-01-21 08:00AM  
Nov-10-21 07:00AM  
Nov-08-21 08:03AM  
Oct-28-21 04:01PM  
Oct-27-21 07:30AM  
Sep-14-21 08:00AM  
Sep-08-21 08:00AM  
Aug-19-21 10:57AM  
Aug-18-21 07:30AM  
Aug-12-21 07:00AM  
Jul-30-21 05:03AM  
Jun-24-21 07:00AM  
Jun-18-21 09:16PM  
Jun-15-21 07:00AM  
Jun-10-21 07:00AM  
May-27-21 07:30AM  
May-21-21 07:41PM  
Apr-30-21 04:44PM  
Apr-29-21 09:19PM  
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, with the help of its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seidel-Dugan CynthiaChief Scientific OfficerJan 12Option Exercise2.8139,731111,838164,888Jan 14 05:58 PM
Leonard ReidChief Operating OfficerDec 15Sale13.413,00040,242122,157Dec 17 04:17 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJun 16Buy13.379,285124,1404,291,881Jun 16 04:58 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJun 15Buy12.957,958103,0564,282,596Jun 16 04:58 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJun 14Buy12.75306,0553,902,2014,274,638Jun 16 04:58 PM